Disease treatment via developing non-syngeneic graft transplantation

• US 8,974,779 B2
• Filed: 10/02/2005
• Issued: 03/10/2015
• Est. Priority Date: 03/06/2003
• Status: Expired due to Fees

• Current Assignee: Yeda Research and Development Co. Ltd. (Weizmann Institute of Science)
• Original Assignee: Yeda Research and Development Co. Ltd. (Weizmann Institute of Science)
• Inventors: Reisner, Yair, Dekel, Benjamin, Eventov-Friedman, Smadar, Katchman, Helena, Shezen, Elias, Aronovich, Anna, Tchorsh, Dalit
• Primary Examiner(s): FOX, ALLISON M
• Application Number:
  US11/664,530
• Publication Number:
  US 20100021433A1
• Time in Patent Office: 3,446 Days
• Field of Search: None
• US Class Current: 424/93.7
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61K 35/26 Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/39 Pancreas; Islets of Langerhans Langerhans cells of epidermis A61K35/36
• CPC Class Codes: A61K 35/42 Respiratory system, e.g. lungs, bronchi or lung cells
• CPC Class Codes: A61L 2430/40 Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/3641 characterised by the site of application in the body materials for artificial blood vessels A61L27/507; materials for use in artificial skin A61L27/60
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

A method of providing a pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function to a mammalian subject is provided. The method comprises transplanting into the subject a developing mammalian pancreatic, lymphoid/hematopietic or pulmonary organ/tissue graft, respectively, thereby generating a functional pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue, respectively, for providing the pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function, respectively, to the subject.

Claims

1. A method of providing a pancreatic function to a human subject, the method comprising transplanting into the subject a porcine pancreatic vascularized organ/tissue graft, wherein said porcine pancreatic vascularized organ/tissue graft is at a gestational stage of about 42 to about 56 days of gestation, thereby generating a functional porcine pancreatic organ/tissue for providing the pancreatic function to the subject.

2. The method of claim 1, wherein the subject has an abnormal activity of a biomolecule naturally produced by a mammalian pancreas.

3. The method of claim 2, wherein said biomolecule is insulin.

4. The method of claim 1, wherein the subject has an abnormal activity of a biomolecule naturally produced by a mammalian pancreatic islet.

5. The method of claim 1, further comprising transiently administering to the subject at least one T-cell costimulation inhibitor and at least one CD40 ligand inhibitor.

6. The method of claim 1, wherein said transplanting said graft into the subject is effected by transplanting said graft under at least one renal capsule of the subject.

7. The method of claim 1, wherein said transplanting said graft into the subject is effected into the pancreas.